Northern Trust Corp grew its holdings in Aduro Biotech, Inc. (NASDAQ:ADRO) by 15.1% during the 2nd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 453,115 shares of the biotechnology company’s stock after acquiring an additional 59,490 shares during the period. Northern Trust Corp owned about 0.62% of Aduro Biotech worth $5,166,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors have also made changes to their positions in ADRO. Legal & General Group Plc lifted its position in shares of Aduro Biotech by 11.2% in the second quarter. Legal & General Group Plc now owns 10,359 shares of the biotechnology company’s stock valued at $118,000 after acquiring an additional 1,043 shares in the last quarter. Tudor Investment Corp ET AL lifted its position in shares of Aduro Biotech by 34.8% in the first quarter. Tudor Investment Corp ET AL now owns 15,436 shares of the biotechnology company’s stock valued at $166,000 after acquiring an additional 3,984 shares in the last quarter. Parametric Portfolio Associates LLC lifted its position in shares of Aduro Biotech by 15.9% in the first quarter. Parametric Portfolio Associates LLC now owns 15,424 shares of the biotechnology company’s stock valued at $166,000 after acquiring an additional 2,119 shares in the last quarter. American International Group Inc. lifted its position in shares of Aduro Biotech by 7.1% in the first quarter. American International Group Inc. now owns 21,840 shares of the biotechnology company’s stock valued at $235,000 after acquiring an additional 1,447 shares in the last quarter. Finally, Nationwide Fund Advisors lifted its position in shares of Aduro Biotech by 12.5% in the second quarter. Nationwide Fund Advisors now owns 23,112 shares of the biotechnology company’s stock valued at $263,000 after acquiring an additional 2,567 shares in the last quarter. Institutional investors and hedge funds own 33.63% of the company’s stock.

Shares of Aduro Biotech, Inc. (NASDAQ ADRO) opened at $8.80 on Friday. Aduro Biotech, Inc. has a twelve month low of $6.01 and a twelve month high of $14.85.

Aduro Biotech (NASDAQ:ADRO) last issued its earnings results on Tuesday, October 31st. The biotechnology company reported ($0.33) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.30) by ($0.03). Aduro Biotech had a negative return on equity of 39.28% and a negative net margin of 548.92%. The firm had revenue of $3.79 million during the quarter, compared to the consensus estimate of $4.04 million. During the same period last year, the firm posted ($0.54) earnings per share. The company’s revenue for the quarter was up .0% compared to the same quarter last year. research analysts predict that Aduro Biotech, Inc. will post -1.28 EPS for the current fiscal year.

In other news, EVP Dirk G. Brockstedt sold 10,000 shares of Aduro Biotech stock in a transaction dated Friday, September 1st. The stock was sold at an average price of $11.69, for a total value of $116,900.00. Following the sale, the executive vice president now directly owns 59,300 shares of the company’s stock, valued at $693,217. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, VP Blaine Templeman sold 3,557 shares of Aduro Biotech stock in a transaction dated Wednesday, September 13th. The stock was sold at an average price of $10.99, for a total value of $39,091.43. Following the completion of the sale, the vice president now directly owns 65,275 shares in the company, valued at $717,372.25. The disclosure for this sale can be found here. Insiders sold 224,480 shares of company stock worth $2,194,001 over the last ninety days. Insiders own 6.60% of the company’s stock.

Several equities analysts have recently commented on ADRO shares. Oppenheimer Holdings, Inc. started coverage on Aduro Biotech in a research report on Monday, October 30th. They issued a “buy” rating and a $15.00 price objective on the stock. HC Wainwright set a $18.00 price objective on Aduro Biotech and gave the company a “buy” rating in a research report on Tuesday, October 17th. BidaskClub upgraded Aduro Biotech from a “hold” rating to a “buy” rating in a research report on Tuesday, July 25th. William Blair restated an “outperform” rating on shares of Aduro Biotech in a research report on Monday, October 2nd. Finally, Canaccord Genuity set a $30.00 price objective on Aduro Biotech and gave the company a “buy” rating in a research report on Thursday, August 3rd. One analyst has rated the stock with a sell rating, one has assigned a hold rating and eight have assigned a buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and an average target price of $19.14.

WARNING: “Aduro Biotech, Inc. (ADRO) Shares Bought by Northern Trust Corp” was published by Daily Political and is the sole property of of Daily Political. If you are reading this article on another publication, it was stolen and reposted in violation of United States & international copyright laws. The correct version of this article can be viewed at https://www.dailypolitical.com/2017/11/18/aduro-biotech-inc-adro-shares-bought-by-northern-trust-corp.html.

Aduro Biotech Profile

Aduro Biotech, Inc is an immunotherapy company, which focuses on the discovery, development and commercialization of therapies that manage the treatment of various diseases, including cancer. The Company’s product candidates from its Live, Attenuated, Double-Deleted (LADD) Listeria monocytogenes, Stimulator of Interferon Genes Pathway Activator, and B-select monoclonal antibody platforms are designed to stimulate and/or regulate innate and adaptive immune responses, either as single agents or in combination with conventional therapies, as well as other immunotherapies.

Institutional Ownership by Quarter for Aduro Biotech (NASDAQ:ADRO)

Receive News & Ratings for Aduro Biotech Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aduro Biotech Inc. and related companies with MarketBeat.com's FREE daily email newsletter.